Paradigm Biopharmaceuticals Limited
Research Paradigm Biopharmaceuticals Limited (PAR.AX) with Bullrun company financials, valuation charts, model signals, and historical stock context.
Key Metrics
- TickerPAR.AX
- ExchangeAU
- CountryAustralia
- SectorHealthcare
- IndustryBiotechnology
- CurrencyAUD
- Financial periodFY2026
- RevenueAUD 80.15K
- Net income-AUD 56.33M
- Free cash flow-AUD 44.18M
- Gross margin84.9%
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2026 | AUD 80.15K | -AUD 56.33M | -AUD 44.18M | 84.9% | -0.15 | AUD 15.37M | AUD 7.51M | AUD 3.47M |
| FY2025 | n/a | n/a | n/a | n/a | -0.06 | n/a | n/a | n/a |
| FY2024 | AUD 65.80K | -AUD 58.65M | -AUD 65.94M | 86.3% | -0.2 | AUD 17.82M | AUD 239.33K | AUD 23.81M |
| FY2023 | AUD 46.76K | -AUD 51.91M | -AUD 45.19M | 59.7% | -0.18 | AUD 56.33M | AUD 341.67K | AUD 53.68M |
| FY2022 | AUD 79.22K | -AUD 39.25M | -AUD 32.21M | -81.4% | -0.16 | AUD 39.67M | AUD 616.67K | AUD 42.31M |
About Paradigm Biopharmaceuticals Limited
Paradigm Biopharmaceuticals Limited engages in the research and development of therapeutic products for human use in Australia. Its lead candidate is Zilosul, an injectable pentosan polysulfate sodium drugs for the treatment of osteoarthritis, mucopolysaccharidosis, chikungunya virus, chronic heart failure, allergic respiratory, and acute respiratory distress syndrome diseases. The company was incorporated in 2014 and is headquartered in Melbourne, Australia.
Related stock research
Other Healthcare stocks
Frequently asked questions
What does Paradigm Biopharmaceuticals Limited do?
Paradigm Biopharmaceuticals Limited engages in the research and development of therapeutic products for human use in Australia. Its lead candidate is Zilosul, an injectable pentosan polysulfate sodium drugs for the treatment of osteoarthritis, mucopolysaccharidosis, chikungunya virus, chronic heart failure, allergic respiratory, and acute respiratory distress syndrome diseases. The company was incorporated in 2014 and is headquartered in Melbourne, Australia.